BC Week In Review | Sep 28, 2018
Financial News

Entasis raises $75M in IPO

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) fell $4.34 (29%) to $10.66 on Sept. 26 after it raised $75 million through the sale of 5 million shares at $15 in its IPO. The offering price valued Entasis...
BC Extra | Sep 26, 2018
Financial News

Entasis dips in first trading day after $75M IPO

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) slipped $4.34 (29%) to $10.66 on Wednesday after it raised $75 million through the sale of 5 million shares at $15 in its IPO. The offering price valued Entasis at...
BC Week In Review | Aug 31, 2018
Financial News

Antibacterial company Entasis proposes NASDAQ IPO

Entasis Therapeutics Inc. (Waltham, Mass.) proposed on Aug. 17 to raise $86.3 million in an IPO on NASDAQ underwritten by Credit Suisse, BMO Capital Markets, SunTrust Robinson Humphrey and Wedbush PacGrow. In September, the antibacterial...
BC Extra | Aug 17, 2018
Financial News

Antibacterial company Entasis proposes NASDAQ IPO

Entasis Therapeutics Inc. (Waltham, Mass.) proposed on Friday to raise $86.3 million in an IPO on NASDAQ underwritten by Credit Suisse, BMO Capital Markets, SunTrust Robinson Humphrey and Wedbush PacGrow. In September, the antibacterial company...
BC Week In Review | Apr 27, 2018
Company News

Zai gets Asia-Pacific license to Entasis' antibiotic combinations

Zai Lab Ltd. (NASDAQ:ZLAB) received an exclusive license to develop and commercialize ETX2514/sulbactam from Entasis Therapeutics Inc. (Waltham, Mass.) in the Asia-Pacific region. The candidate is in Phase II testing to treat severe Acinetobacter baumannii...
BC Week In Review | Oct 13, 2017
Clinical News

Entasis reports Phase I data for anti-infective ETX2514

Entasis Therapeutics Inc. (Waltham, Mass.) reported data from a double-blind, placebo-controlled, Australian Phase I trial in 124 healthy volunteers showing that single and multiple ascending doses of IV ETX2514 given alone or in combination with...
BioCentury | Sep 8, 2017
Finance

Antibiotic engine

A combination of non-dilutive funding and a newly-raised $31.9 million series B-1 round should give Entasis Therapeutics Inc. enough cash to see its lead candidate all the way through commercialization and to move two others...
BC Week In Review | Nov 2, 2016
Clinical News

ETX2514: Ph I started

Entasis began a double-blind, placebo-controlled, Australian Phase I trial to evaluate single and multiple ascending doses of 0.25-8 g IV ETX2514 with or without sulbactam or imipenem/cilastatin in about 124 healthy volunteers. Entasis Therapeutics Inc....
Items per page:
1 - 8 of 8